Zhang L - Search Results

1

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer.

Que Y, Wang J, Zhu J, Li N, Huang J, Lu S, Sun F, Zhang L, Zhen Z, Zhang L, Cai R, Guo H, Sun X, Zhang Y. Que Y, et al. Among authors: zhang l, zhang y. Front Immunol. 2021 Jul 6;12:647733. doi: 10.3389/fimmu.2021.647733. eCollection 2021. Front Immunol. 2021. PMID: 34295326 Free PMC article. Clinical Trial.

2

Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer.

Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, Fang W, Chen X, Zhang Y, Zou B, Li Q, Wan Y, Chen H, Tang Y, Zhao J, Weng D, Xia L, Zhang L, Xia J. Liu H, et al. Among authors: zhang l, zhang y. Clin Transl Immunology. 2020 Oct 9;9(10):e1154. doi: 10.1002/cti2.1154. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33072320 Free PMC article.

3

Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.

Zhou T, Zhang Z, Luo F, Zhao Y, Hou X, Liu T, Wang K, Zhao H, Huang Y, Zhang L. Zhou T, et al. Among authors: zhang l, zhang z. JAMA Netw Open. 2020 Oct 1;3(10):e2015748. doi: 10.1001/jamanetworkopen.2020.15748. JAMA Netw Open. 2020. PMID: 33074323 Free PMC article.

4

Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.

Wang C, Sun C, Li M, Xia B, Wang Y, Zhang L, Zhang Y, Wang J, Sun F, Lu S, Zhu J, Huang J, Zhang Y. Wang C, et al. Among authors: zhang l, zhang y. J Cell Physiol. 2021 Jun;236(6):4470-4481. doi: 10.1002/jcp.30163. Epub 2020 Nov 18. J Cell Physiol. 2021. PMID: 33206395

5

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.

Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, Dang T, Sadowski S, Kush DA, Zhou Y, Li B, Mok T. Wu YL, et al. Among authors: zhang l, zhang x. Int J Cancer. 2021 May 1;148(9):2313-2320. doi: 10.1002/ijc.33399. Epub 2020 Dec 9. Int J Cancer. 2021. PMID: 33231285 Free PMC article. Clinical Trial.

6

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study.

Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L. Zhao S, et al. Among authors: zhang l, zhang z, zhang y. Front Oncol. 2020 Nov 10;10:587849. doi: 10.3389/fonc.2020.587849. eCollection 2020. Front Oncol. 2020. PMID: 33244458 Free PMC article.

7

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.

He LN, Zhang X, Li H, Chen T, Chen C, Zhou Y, Lin Z, Du W, Fang W, Yang Y, Huang Y, Zhao H, Hong S, Zhang L. He LN, et al. Among authors: zhang l, zhang x. Front Oncol. 2021 Jan 19;10:621329. doi: 10.3389/fonc.2020.621329. eCollection 2020. Front Oncol. 2021. PMID: 33552993 Free PMC article.

8

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer.

Fang W, Jin H, Zhou H, Hong S, Ma Y, Zhang Y, Su X, Chen L, Yang Y, Xu S, Liao Y, He Y, Zhao H, Huang Y, Gao Z, Zhang L. Fang W, et al. Among authors: zhang l, zhang y. Mol Cancer. 2021 Feb 23;20(1):37. doi: 10.1186/s12943-021-01331-9. Mol Cancer. 2021. PMID: 33622313 Free PMC article. No abstract available.

9

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.

Ma Y, Chen X, Wang A, Zhao H, Lin Q, Bao H, Zhang Y, Hong S, Tang W, Huang Y, Yang Y, Wu X, Shao Y, Fang W, Zhang L. Ma Y, et al. Among authors: zhang l, zhang y. J Immunother Cancer. 2021 Mar;9(3):e002014. doi: 10.1136/jitc-2020-002014. J Immunother Cancer. 2021. PMID: 33737344 Free PMC article.

10

Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report.

Li YH, Zhou Y, Liu YY, Zhang GJ, Xiao L, Li N, Qin HF, Wang JG, Zhang L. Li YH, et al. Among authors: zhang l, zhang gj. Thorac Cancer. 2021 Jun;12(11):1780-1783. doi: 10.1111/1759-7714.13967. Epub 2021 May 5. Thorac Cancer. 2021. PMID: 33949137 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135,504 results

Search Page

Filters